ADCendo ApS is a biotech company developing novel antibody-drug-conjugates for treatment of selected bone, connective tissue and brain cancers.
The technology of ADCs is inherited from the research work by its scientific founders during the work at the Finsen Laboratory relating to antibody drug conjugate drugs targeting the uPARAP receptor.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Antibody-drug conjugates (ADCs) are an advanced class of therapeutic agents, which combine the effects of several biological components and processes to achieve targeted drug delivery to cancer cells. By combining antibodies with cytotoxic compounds and linkers possessing certain properties, ADCs which are highly efficient at targeting and killing cancer cells can be obtained, based on the particular characteristics of a given type of cancer.
Pipeline
ADCendos first drug candidate is an ADC targeting the uPARAP receptor. This receptor is highly expressed in several bone, connective tissue and brain cancers – Sarcomas and Glioblastomas.
Partnering Activities
In Nov 2017, ADCendo ApS, the University of Copenhagen and the Capital Region of Denmark entered into a license agreement with the aim of developing novel, targeted cancer treatments against certain bone, connective tissue and brain cancers. ADCendo worldwide rights to explore and commercialize certain inventions made by researchers at the Finsen Laboratory related to Antibody Drug Conjugate (ADC) drugs targeting the novel uPARAP receptor.
ADCendo has secured funding for its early preclinical activities and is in discussions with potential investors regarding the funding needed for scaling up, IND enabling tox and preparation for and making phase 1/2 studies.
Recover your password.
A password will be e-mailed to you.